Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Maternal medications linked to changes in protein and fat levels in human milk

Breast milk from mothers on antidepressants or anti-inflammatory drugs shows reduced protein and fat levels In a recent study published in the JAMA Network Open, a group of researchers investigated the association between maternal use of antidepressant and ant

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Breast milk from mothers on antidepressants or anti-inflammatory drugs shows reduced protein and fat levels

In a recent study published in the JAMA Network Open, a group of researchers investigated the association between maternal use of antidepressant and anti-inflammatory medications and the macronutrient composition of human milk.

Background

Breastfeeding provides significant health benefits for both mother and infant and is recommended as the exclusive source of nutrition for the first six months. Human milk contains carbohydrates (primarily lactose at 8 g/100 mL), fat (3.5-4 g/100 mL), and protein (1 g/100 mL), with a total energy content of 66 kcal/100 mL. Macronutrient levels naturally vary due to factors like feeding frequency, infant age, maternal body mass index (BMI), and diet.

Over 70% of breastfeeding mothers use medications, yet their impact on milk composition remains unclear. Further research is needed to understand how medications may influence macronutrient levels in human milk.

About the study

The present study collected exposure data and milk samples from October 2014 to January 2024 through the University of California, San Diego Human Milk Biorepository.

Participants included mothers of singleton infants, with milk samples collected between 2 weeks and 12 months postpartum. Of 3,366 samples meeting inclusion criteria, 310 were from mothers on long-term medication and 3056 from untreated mothers.

Medicated mothers were categorized into four groups based on exposure: selective serotonin reuptake inhibitors (SSRIs), monoclonal antibodies (MABs), systemic corticosteroids, and other anti-inflammatory drugs (ADs). Samples from mothers exposed to multiple medications were excluded.

Maternal health conditions and mood disorders were assessed via interviews and the Edinburgh Postnatal Depression Scale. Untreated mothers with inflammatory or mood disorders served as disease-matched controls (DMCs), while healthy controls were frequency-matched by infant age and sex.

Milk macronutrients (carbohydrates, fat, protein, and total energy) were measured using near-infrared spectroscopy. Statistical analysis adjusted for covariates such as maternal and infant age, BMI, breastfeeding exclusivity, feeding frequency, collection time, and maternal cannabis use.

Study results

The study analyzed 384 milk samples, including 63 exposed to SSRIs, 63 to MABs, 33 to systemic steroids, 20 to other ADs, 141 from DMCs, and 64 from healthy, unmedicated mothers. Among the mothers, 7.0% were Asian, 12.5% non-Hispanic Black, 12.5% Hispanic, 75.8% non-Hispanic White, and 2.9% from other racial or ethnic groups.

The cohort included 50.5% female infants, with mean (SD) maternal and infant ages of 33.5 (4.4) years and 6.6 (5.4) months, respectively. Healthy control mothers were younger than exposed and DMC mothers, but no differences were found in infant age across groups.

Mothers treated with SSRIs had a significantly higher mean (SD) BMI of 29.9 (6.8) compared with other groups. Cannabis use was lower among mothers treated with ADs than in other groups, with no significant differences in race, parity, infant sex, exclusive breastfeeding, or socioeconomic factors. Missing data on sample collection time, maternal occupation, household income, and feeding frequency ranged from 3.6% to 12.5%.

Mood disorder prevalence was lower in SSRI-treated mothers compared to DMCs (92.1% vs. 100%), while inflammatory disorder prevalence was lower among AD-treated groups compared to DMCs.

Macronutrient analysis showed mean (SD) levels of carbohydrates, fat, protein, and total energy as 8.41 (2.19) g/100 mL, 4.06 (1.74) g/100 mL, 0.92 (0.53) g/100 mL, and 78.15 (22.35) kcal/100 mL, respectively.

Carbohydrate levels showed no significant differences between groups. Protein content was 15% to 21% lower in all exposed groups compared to healthy mothers, but after adjustments, the difference remained significant only for SSRIs and steroids.

Fat and energy levels were 10% to 22% lower in samples from mothers treated with other ADs compared to DMC and healthy controls. Adjusted analyses revealed significant differences only in fat content when compared to DMCs.

Conclusions

To summarize, this study is the first to investigate the relationship between long-term maternal medication use and macronutrient composition in human milk. While carbohydrate levels remained consistent, protein and fat levels showed significant variations among exposed groups. Although mean values were within reference ranges, some samples had notably low macronutrient levels.

The clinical implications of these differences are unclear, particularly for preterm or ill infants, who may face growth or health risks if nutrient deficits go undetected. Factors such as maternal diet, nutrient stores, and disease severity might influence milk composition and could represent unmeasured confounders.

  • Whaites Heinonen E, Bertrand K, Chambers C. Macronutrients in Human Milk Exposed to Antidepressant and Anti-Inflammatory Medications. JAMA Netw Open. (2025) doi:10.1001/jamanetworkopen.2024.53332 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2828756

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Are supplements necessary?

Daily, if you eat a balanced diet that includes healthy foods, you technically should not need a vitamin supplement. A healthy diet incorporates lean proteins, healthy fats, grains, fruits, and vegetables. But if you do not have a balanced diet, you may be considering hair, skin, and nail vitamins. Some people prefer supplements, sometimes choosing a multivitamin that can supply all of your essential minerals and vitamins. But taking too much of vitamins or unnecessary supplements is wasteful because the body gets rid of excess vitamins and minerals or, worse, it can be dangerous. The following is a guide to choosing which vitamins you may want to consider supplementing and when. Deficiencies in the nutrients that keep the skin, hair, and nails healthy can cause changes over time. For example, not enough intake of vitamins A and E, along with not enough biotin, can cause scaly and rough skin patches, eczema, and hair loss. If there is a deficiency, vitamins will help. However, if there is no deficiency, there is no clear evidence that supplements will make a difference. No research studies concluded that supplements treat or prevent age-related, natural hair damage or loss or lead to healthier skin. Two studies in the early 1990s did suggest that a biotin supplement may cause the hair to become stronger and strengthen weak nails. However, the studies were small and not reproduced.

Source: www.medicinenet.com ↗
02What comes next?

We are now testing the drug in patients with earlier-stage pancreatic cancer, prescribing it while their tumors are still operable and before their cancer spreads.

Source: www.news-medical.net ↗
03In safety assessment, the consequences of being wrong are significant. How do you think about uncertainty and model limitations for safety and discovery?

Uncertainty and model limitations are critical in safety assessment. There is clearly greater potential for animal or human harm from an incorrect safety assessment than from making the wrong molecule in early discovery, although uncertainty matters in both contexts. It is important to distinguish different types of uncertainty. Aleatoric uncertainty reflects irreducible randomness in a task, while epistemic uncertainty is model-related, such as hallucinations or lack of knowledge. For LLM systems, we use multiple methods to measure consistency and we have built fact-checking approaches in which a separate LLM independently verifies the primary engine's outputs. For QSAR models, including our SAR work around seizure liability, we can use statistical metrics such as confidence intervals to quantify and communicate uncertainty. Understanding that uncertainty exists and communicating it in both safety and discovery is critical. Uncertainty metrics tell us where potential blind spots may exist in our modelling allowing us to take action to improve over time. This applies to both safety and discovery. The aim is not to pretend AI removes uncertainty, but to make uncertainty visible so scientists can make better-informed decisions. Download the Full PDF to Revisit James McDonagh's Insights on AI in Drug Safety Discovery

Source: www.news-medical.net ↗
04Can you please give an overview of BenevolentBio?

What we're trying to do here at Benevolent is develop systems and processes that allow us to tap into the huge amount of public information and some propriety databases that we have paid to access and through that, generate hypotheses which our scientists can then triage. We've got over ten times the amount of information in our database at present (and it’s growing) than we believe that companies such as Watson have. Bringing that and filtering the signals from the ‘noise’ to our experienced drug discovery chemists and biologists, means, firstly, we can reduce the amount of time we take to triage new hypotheses, and secondly, we can develop more predictive chemical tools to allow us to make better molecules and also to reposition existing molecules for new indication.

Source: www.news-medical.net ↗
05From Spirulina to Seaweed: How are different types of algae integral to human diets?

Algae are photosynthetic aquatic creatures that grow through the consumption of nutrients, light, and carbon dioxide. They are a diverse group of creatures that include tiny single-celled algae and enormous kelp, as well as seaweed 1. Numerous prokaryotic and eukaryotic algae species are desirable food sources for humans due to their inherent qualities 2,3. Human intake of macroalgae such as seaweed and microalgae like phytoplankton dates back many years. Multicellular macroscopic aquatic plants, or macroalgae, are classified into three taxa: Phaeophyceae, or brown algae, Rhodophyta or red algae, and Chlorophyta or green algae. Microalgae, the unicellular counterpart of macroalgae, are categorized in a broader framework that includes prokaryotic cyanobacteria (blue-green algae), Euglenophyta, and Chlorophyta, which are genetically distinct from one another. The ancient populations of Chad and the Aztec culture were already familiar with the cyanobacteria spirulina, which is currently advertised as a superfood in the West 4. In Burma, Vietnam, and India, other cyanobacteria/microalgae, like Spirogyra and Oedogonium, were eaten as food or as a supplement 4. Seaweed is a staple of daily meals in many Asian and Pacific civilizations, including Korea, Japan, and Indonesia, as well as Hawaii and New Zealand 5.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides